Prostate RT 80 vs 70 Gy with ADT: no added severe toxicity

Editor's Pick: High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial (The Lancet Oncology, 2026)
Welcome to This Week in Oncology. This week we're covering 10 notable papers spanning long-term adjuvant therapy across breast, kidney and lung cancer, radiotherapy dose and fractionation questions in prostate cancer, and new immunotherapy and combination strategies in liver, lung and colon cancer. Let's dive in.
This week's papers:
• Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42648402)
• Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2-associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial. — Annals of Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42636977)
• Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42647767)
• High-dose radiotherapy in patients with high-risk prostate cancers treated with long-term androgen deprivation therapy (GETUG AFU 18): a randomised, phase 3 trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42636837)
• Durvalumab and tremelimumab, with or without lenvatinib, combined with transarterial chemoembolisation in participants with embolisation-eligible hepatocellular carcinoma (EMERALD-3): a global, randomised, open-label, sponsor-blinded, phase 3 study. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42636832)
• Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42636833)
• Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42641124)
• Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial. — The Lancet Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42636834)
• Omitting Bone Marrow Sampling in FDG-Avid Rhabdomyosarcoma With 2-[18F]FDG PET-Negative Marrow: Results From an International Retrospective Study. — Journal of Clinical Oncology 2026 (pubmed.ncbi.nlm.nih.gov/42636421)
• Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial. — Clinical Cancer Research 2026 (pubmed.ncbi.nlm.nih.gov/42644724)
Listen at AudioScholar (audioscholar.cc/episode/zv4n5ws7ru)